arrow
L

Laura San-Segundo

University System of Ohio
H指数:20
被引数:1,659

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TRANSLATIONAL STEPS OF THE ANTITUMOR PEPTIDE TAT-CX43266-283 AS A TREATMENT FOR GLIOBLASTOMA: EGFR AS A TREATMENT RESPONSE BIOMARKER AND RESULTS OF COMBINATION THERAPY IN A PRECLINICAL RESECTION MODEL
2024-11-110
PRE
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
CELLS
IF5.2
2021-03-044
OAAI
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
2021-01-1832
OAAI
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
LEUKEMIA
IF13.4
2020-01-2325
OAAI
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
2019-07-1846
OAAI
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
2017-08-3118
OAAI
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
2017-06-2032
OAAI
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
LEUKEMIA
IF13.4
2014-11-1264
OAAI
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

骨髓瘤获得性耐药的体内小鼠模型揭示了来那度胺和波马利度胺与地塞米松联合使用的差异机制

LEUKEMIA
IF13.4
2014-08-0871
PREAI